EGFR and glioma: For instance, isocitrate dehydrogenase (IDH) mutations and chromosome 1p/19q codeletion as positive prognostic markers in adult patients, indicating longer survival22; H3F3A alterations predict worse outcomes in pediatric glioma patients23; TERT promoter mutations and EGFR alterations lead to IDH‐wildtype astrocytoma reaching the highest tumor grade with the worst prognosis.24